Abstract

Since the last CCSG renewal, Development Funds have supported 1) the recruitment of ten outstanding early career investigators, 2) development of two new shared resources and implementation of eight new services in existing shared resources, and 3) partial funding for fourteen MD Anderson Multidisciplinary Research Program (MRP) awards. The $500,000 of CCSG support for faculty recruitment has leveraged over $5.0M in MD Anderson start-up packages and more than $29.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of P01, SPORE, and CPRIT multi-investigator grant applications. Since the inception of the program in 1997, MD Anderson has invested $11.2M in MRP grants. These awards have been associated with external peer-reviewed funding of more than $157M, representing a 14.1-fold return on investment. During the present grant cycle, 17 proposals have been supported with $625,000 from CCSG Development Funds matched approximately 5:1 with institutional funds. This investment of CCSG support has leveraged $18.6M in extramural funding to date, with $8.8M from Multi-PI awards and $9.8M from individual investigator awards that resulted from projects supported as part of an MRP. Development Funds supported establishing the Functional Genomics Core (FGC) and the Assessment, Intervention and Measurement (AIM) core. In the current CCSG application, Development Funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for four developing shared resources: the Oncology Research and Immuno-Monitoring Core (ORION), the Microbiome Core Facility, the Shared Decision Making (SDM) Core, and the Metabolomics Core. Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources and to fund collaborative pilot projects within and between programs are also proposed.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997888
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Roland, Christina L; Bednarski, Brian K; Watson, Kelsey et al. (2018) Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol 117:879-885
Gulhati, Pat; Raghav, Kanwal; Shroff, Rachna et al. (2018) Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist 23:277-e26
Bhattacharya, Rajat; Ellis, Lee M (2018) It Is Time to Re-Evaluate the Peer Review Process for Preclinical Research. Bioessays 40:
Boddu, Prajwal; Oviedo, Sergio Pina; Rausch, Caitlin R et al. (2018) PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 59:1486-1489
Assi, Rita; Garcia-Manero, Guillermo; Ravandi, Farhad et al. (2018) Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124:4192-4201
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Luo, Yangkun; Xu, Yujin; Liao, Zhongxing et al. (2018) Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis? Acta Oncol :1-7
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Liu, Yihua; Weber, Zachary; San Lucas, F Anthony et al. (2018) Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. Gynecol Oncol 151:243-249
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008

Showing the most recent 10 out of 12418 publications